Abstract
Introduction

25
Cigarette smoke is the leading cause of preventable death, accounting for 1 in 5 deaths in 26 the United States and nearly six million deaths annually worldwide, with mortality rates rising
27
(1). Exposure to cigarette smoke causes many diseases, including chronic obstructive pulmonary 28 disease (COPD, comprised of chronic bronchitis and emphysema) and an increased susceptibility 29 to bacterial infections, such as those from Non-typeable Haemophilus influenzae and
30
Streptococcus pneumoniae (42, 72) . Chronic inflammation underlies most cigarette smoke-31 induced diseases. In particular, chronic activation of macrophages by cigarette smoke promotes 32 tissue destruction and can lead to COPD (60, 72) . Macrophages produce cytokines that stimulate 33 excess mucus production and lead to chronic bronchitis. Additionally, macrophages are 34 increased in emphysematous lungs, and have increased proteinase activity, reactive oxygen 35 species (ROS) production, and secretion of inflammatory cytokines (60, 72) . Despite this chronic 36 inflammatory activation, patients with COPD are also more susceptible to bacterial and viral 37 infections (42, 65), due at least in part to an impairment in macrophage phagocytic abilities; 38 these defects in phagocytosis also lead to impaired clearance of apoptotic cells (20, 33, 38, 43, 39 47). Clearly, the underlying inflammatory mechanisms involved in cigarette smoke exposure and 40 the progression of COPD are complex and inadequately addressed through the current standard 41 treatments, which primarily involve bronchodilators and immunosuppressive steroids.
42
In the past, the resolution of inflammation was thought to be passive.
43
Resolution, however, is now known to be an active and dynamic process (7). Recent 44 investigations have led to the discovery of specialized pro-resolving mediators (SPMs). These 
77
ALX/FPR2-specific antagonist Boc-2 was purchased from Genscript (Piscataway, NJ). A 78 GPR32-neutralizing Ab (GX71225) was purchased from GeneTex (Irvine, CA). Antibodies to 79 CD11b (560914) and CD14 (555398) and ELISA components for IL-6 (554543 and 554546) and 
COPD patients have dysregulated lipid mediator levels
172
The chronic inflammatory causes of COPD can be viewed as a failure to resolve inflammation.
173
To explore this idea, we first investigated the levels of pro-resolving lipid mediators in COPD 174 and non-COPD human exhaled breath condensate (EBC) and bronchoalveolar lavage fluid 175 (BALF). Using LM-metabololipidomics (15), we identified by matching criteria and MS/MS 176 spectra, bioactive LM, RvD1 and pathway markers 17-hydroxyl docosahexaenoic acid HDHA) and 14-HDHA, in both healthy and COPD EBCs, (Fig. 1A (Fig. 1E-F ). LxA4, a potential confounder due to crossreactivity in the ELISA, was not 183 detected in our BALF and has been found at extremely low levels in human serum, making the 184 likelihood of cross-reactivity very low (52, 53) . This is the first evidence that COPD patients 185 have dysregulated levels of the omega-3 derived SPMs. 196 with the most consistent effect seen at 100nM ( Fig. 2A-B) . We next investigated the efficacy of 197 100nM RvDs in both COPD and non-COPD patients. RvD1 and RvD2 dampened spontaneous 198 production of TNFα, though not IL-8; RvD2 additionally dampened production of IL-6 and 199 enhanced phagocytic uptake of E. coli by unstimulated human alveolar macrophages ( Fig. 2C-F ).
200
We also examined COPD and non-COPD populations separately (Table 2 ). RvD1 and RvD2
201
were efficacious on both COPD and non-COPD alveolar macrophages, with stronger potency on 202 non-COPD patients, demonstrating further their potential efficacy in humans as potential 203 therapeutics (Table 2) . In order to characterize the effects of SPMs on human macrophages, we conducted further 208 experiments using macrophages derived from peripheral blood monocytes. Blood derived 209 monocytes from multiple healthy human donors were isolated to >95% purity (Fig. 3A) , differentiated to macrophages, and incubated with 100 nM SPMs for 24 hrs. Based on our human 211 lipid profiles, efficacy with alveolar macrophages, and screening of multiple SPMs and 17-212 HDHA ( Fig. 3B-C ), RvD1 and RvD2 were chosen for these studies; we used 1nM and 100nM of 213 SPMs based on preliminary dose curve studies in blood-derived macrophages (data not shown) 214 and our results with BAL macrophages ( Fig. 2A-B) . Following SPM treatment, cells were 215 exposed to CSE for 24 hrs. Neither SPMs nor CSE at the indicated doses affected cell viability 216 (Fig. 3D) . CSE increased production of the pro-inflammatory mediators 217 cytokines important in propagating an immune response, attracting neutrophils, enhancing 218 phagocytosis and promoting cell death. RvDs completely attenuated IL-6 increases ( Fig. 4A ) and 219 dose-dependently dampened IL-8. 1nM RvD1 and both doses RvD2 additionally dampened 220 TNF-α expression ( Fig. 4B-C) . In addition to preventing pro-inflammatory cytokine release,
221
resolvins promote a resolution phenotype in macrophages and the production of anti-222 inflammatory cytokines. CSE decreased production of the anti-inflammatory cytokine IL-10 223 ( Fig. 4D ), but this effect was not attenuated by SPMs. Conversely, RvD1 increased 224 concentrations of total TGF-β, and RvD2 increased concentrations of both active and total TGF-225 βhad an increased ratio of active/total TGF-β, an anti-inflammatory cytokine important in tissue 226 repair ( Fig. 4E-G macrophages. (Fig. 6A-B) . RvD treatment, however, did not dampen this initial oxidative burst 258 20 min (data not shown) or 1 hour after CSE exposure (Fig. 6A-B) . We additionally investigated
259
RvD1 and RvD2 actions on carbonylated proteins; reactive oxygen species can induce the 260 modification of native amino acids to carbonyl derivatives. RvDs did not significantly affect 261 levels of carbonyl groups at 1 hour after smoke exposure (Fig. 6C-D RvD2 and exposed to CSE. CSE impaired uptake of fluorescently labeled E. coli ( Fig. 7A-B) .
272
RvDs incubation prevented these decreases and restored macrophage phagocytic abilities (Fig. 273 7A-B). In addition, CSE decreased the number of macrophages that phagocytized bacteria, a 274 decrease which was rescued by RvDs (Fig. 7C) . Resolvin D1 is known to signal through two receptors-ALX and GPR32; the receptors for RvD2 278 are currently unknown (4, 34, 45 pathway. CSE had no effect on p100 expression, but increased expression of the cleaved p52 296 product ( Fig. 9E-F ). This increase in p52 was reduced by RvD2, though p100 expression 297 remained unchanged. Interestingly, CSE caused a dramatic loss of RelB expression, which was 298 significantly prevented by RvD2 ( Fig. 9G-H ). These studies support changes in NF-κB 299 expression as a possible mechanism for resolvins, and include evidence for the first time 300 supporting the involvement of the alternative NF-κB pathway. 
334
SPMs have both anti-inflammatory and pro-resolving effects. They have been shown to 335 not only reduce the production of pro-inflammatory proteins, but to induce a phenotypic shift in 336 cells to promote anti-inflammatory effects and alternative M2 activation (7, 16, 49, 57, 71) . with differential effects, which may account for increases in expression with both smoke and 364 RvDs (25, 28). PGD 2 also counterregulates expression of PGE 2 and is converted to 15-365 deoxyPGJ 2 , which has pro-resolution properties that may result from inhibition of 366 32, 58, 59). Although PGE2 is often considered a pro-inflammatory mediator, it also has anti-367 inflammatory properties, including the ability to reduce IL-6 levels and suppress allergic airway 368 inflammation (6, 32, 37, 79) 
. PGE2 also upregulates IL-10 (REF). It is interesting in this context
369 that RvD1 and RvD2 inhibit IL-6 production but do not upregulate IL-10; we cannot rule out the 370 possibility that the absence of IL-10 is due to reduced PGE 2 production. The mechanisms by 371 which SPMs regulate other lipids appear to be complicated and merit in depth investigation. 
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